LMAT vs. ATEC, IART, MDXG, NVCR, ATRC, ICUI, CATX, AORT, NARI, and SILK
Should you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include Alphatec (ATEC), Integra LifeSciences (IART), MiMedx Group (MDXG), NovoCure (NVCR), AtriCure (ATRC), ICU Medical (ICUI), Perspective Therapeutics (CATX), Artivion (AORT), Inari Medical (NARI), and Silk Road Medical (SILK). These companies are all part of the "surgical & medical instruments" industry.
LeMaitre Vascular (NASDAQ:LMAT) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation.
In the previous week, Alphatec had 2 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for Alphatec and 4 mentions for LeMaitre Vascular. Alphatec's average media sentiment score of 0.62 beat LeMaitre Vascular's score of 0.60 indicating that Alphatec is being referred to more favorably in the news media.
84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 66.4% of Alphatec shares are held by institutional investors. 10.8% of LeMaitre Vascular shares are held by insiders. Comparatively, 22.8% of Alphatec shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
LeMaitre Vascular has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
LeMaitre Vascular has a net margin of 16.99% compared to Alphatec's net margin of -37.45%. LeMaitre Vascular's return on equity of 11.57% beat Alphatec's return on equity.
LeMaitre Vascular has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.
LeMaitre Vascular presently has a consensus price target of $73.83, suggesting a potential downside of 7.42%. Alphatec has a consensus price target of $22.89, suggesting a potential upside of 126.17%. Given Alphatec's stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than LeMaitre Vascular.
LeMaitre Vascular received 187 more outperform votes than Alphatec when rated by MarketBeat users. Likewise, 70.86% of users gave LeMaitre Vascular an outperform vote while only 56.68% of users gave Alphatec an outperform vote.
Summary
LeMaitre Vascular beats Alphatec on 10 of the 18 factors compared between the two stocks.
Get LeMaitre Vascular News Delivered to You Automatically
Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LeMaitre Vascular Competitors List
Related Companies and Tools
